Abstract 105P
Background
Anti-angiogenesis inhibitors have shown enhanced antitumor activity when combined with PD-1 inhibitors in patients with metastatic colorectal cancer (mCRC). The study aimed to forecast the prognosis and identify the influential factors associated with the therapeutic combination of VEGFR-TKIs and PD-1 inhibitors in patients with microsatellite-stable (MSS) mCRC.
Methods
We conducted a retrospective study of MSS mCRC patients treated with VEGFR-TKI coupled with PD-1 inhibitors from January 2020 to April 2024. Kaplan-Meier curves were generated for OS. Boruta algorithm and LASSO-Cox regression model were applied to identify key features associated with OS in our clinical dataset, which comprises 34 features including age, sex, primary location, differentiation, RAS status, metastatic sites, treatment lines, the treatment duration of VEGFR-TKIs and the treatment cycles of PD-1 inhibitors, etc. Restricted cubic splines (RCS) were used to estimate the effects of key features on OS.
Results
The study enrolled 79 eligible patients, with a median age of 57 years (range, 24-81), and 65.8% were male. The most frequently utilized VEGFR-TKI was fruquintinib. The median number of previous treatment lines was two. Median OS was 27.1 months (95% CI 20.6–NA). Median PFS was 5.7 months (95% CI 4.3–7.9). LASSO-Cox regression identified four signature features: sex, primary location, differentiation, and the treatment duration of VEGFR-TKIs, which highly influenced the OS. Boruta algorithm identified the treatment duration of VEGFR-TKIs as the only key feature influencing the OS of patients. RCS results suggested an approximately linear relationship between the hazard ratio (HR) for OS and the treatment duration of VEGFR-TKIs (P = 0.0234, P for non-linearity = 0.630), and the treatment duration of fruquintinib longer than 2.8 months was significantly associated with longer OS.
Conclusions
The machine learning findings indicate that the duration of VEGFR-TKI treatment impacts OS in patients with MSS mCRC, a treatment duration of fruquintinib exceeding 2.8 months was found to have a significant positive influence on OS for patients with MSS mCRC.
Legal entity responsible for the study
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
226P - Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment
Presenter: Manuel Cabeza Segura
Session: Poster Display session
Resources:
Abstract
228P - Modulating mitochondrial dynamics in TAMs to enhance anti-tumor immunity
Presenter: Pu-ste Liu
Session: Poster Display session
Resources:
Abstract
229P - Investigation of the effects of long-noncoding RNA NRAV on interferon response in melanoma
Presenter: Kadir Durmus
Session: Poster Display session
Resources:
Abstract
230P - Deciphering the mechanism of immunosuppressive activity of acetaminophen in the context of cancer immunotherapy
Presenter: Jeanne Lena
Session: Poster Display session
Resources:
Abstract
231P - The impact of calcitriol and tacalcitol on the Th17 lymphocytes in breast cancer
Presenter: Beata Filip-Psurska
Session: Poster Display session
Resources:
Abstract